Syndetics omslagsbild
Bild från Syndetics

F. Hoffman-LaRoche Ltd. : Avastin and a crisis in patient blindness / Sourya Biswas, Mike Gedjeyan, James S. O'Rourke.

Av: Medverkande: Materialtyp: TextSerie: Utgivningsuppgift: London : SAGE Publications Ltd, 2017Beskrivning: 1 online resource : illustrationsInnehållstyp:
  • text
Medietyp:
  • computer
Bärartyp:
  • online resource
ISBN:
  • 9781526408464 (ebook) :
Ämnen: DDK-klassifikation:
  • 338.476151091724
Onlineresurser: In spite of similar formulation, Swiss pharmaceutical's giant Roche has always positioned its two products Avastin and Lucentis separately, as treatments for cancer and for age-related macular degeneration (AMD) respectively. However, doctors have been prescribing Avastin for AMD treatments because of the huge price differential between the two drugs. With contamination of Avastin due to repackaging by a Florida pharmacy leading to 21 cases of patient blindness in Q3 2011, Roche faces a serious threat to its reputation and finances.
Inga fysiska exemplar för denna post

Originally published in Biswas, S., Gedjeyan, M., & ORourke, J. S. (2011). F. Hoffman-LaRoche Ltd.: Avastin and a crisis in patient blindness. 11-09. Notre Dame, IN: The Eugene D. Fanning Center for Business Communication, Mendoza College of Business, University of Notre Dame.

In spite of similar formulation, Swiss pharmaceutical's giant Roche has always positioned its two products Avastin and Lucentis separately, as treatments for cancer and for age-related macular degeneration (AMD) respectively. However, doctors have been prescribing Avastin for AMD treatments because of the huge price differential between the two drugs. With contamination of Avastin due to repackaging by a Florida pharmacy leading to 21 cases of patient blindness in Q3 2011, Roche faces a serious threat to its reputation and finances.

Description based on XML content.

Licensed e-book